UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The lancet oncology, 2024-04, Vol.25 (4), p.439-454

2024

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

JTO clinical and research reports, 2021-11, Vol.2 (11), p.100234, Article 100234

2021

Volltextzugriff (PDF)

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical cancer research, 2019-04, Vol.25 (7), p.2088-2095

2019

Volltextzugriff (PDF)

Targeting EGFR in Lung Cancer: Current Standards and Developments

Drugs (New York, N.Y.), 2018-06, Vol.78 (9), p.893-911

2018

Volltextzugriff (PDF)

Targeting TIGIT: Strengthening the Immune Checkpoint Blockade

Oncology (Williston Park, N.Y.), 2021-01, Vol.35 (1), p.44

Rodriguez, Luis Paz-Ares

2021

Volltextzugriff (PDF)

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2490-2498

2017

Volltextzugriff (PDF)

Targeting EGFR in Lung Cancer: Current Standards and Developments

Drugs (New York, N.Y.), 2018-06, Vol.78 (9), p.893-911

2018

Volltextzugriff (PDF)

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A811-A811

2023

Volltextzugriff (PDF)

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

The lancet oncology, 2018-04, Vol.19 (4), p.521-536

2018

Volltextzugriff (PDF)

Necitumumab: a new option for first-line treatment of squamous cell lung cancer

Expert opinion on drug metabolism & toxicology, 2018-08, Vol.14 (8), p.765-772

2018

Volltextzugriff (PDF)

Impacto psicológico del COVID-19 en los pacientes de Oncología Médica, Hemato-Oncología y Oncología Radioterápica de un hospital público en España

Psicooncología, 2023-10, Vol.20 (2), p.305-328

2023

Volltextzugriff (PDF)

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of clinical oncology, 2024-07, Vol.42 (19), p.2317-2326

2024

Volltextzugriff (PDF)

PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e34-e34

2024

Volltextzugriff (PDF)

O25-3. Tarlatamab in small cell lung cancer : safety and efficacy analyzed by baseline brain metastasis

Japanese Journal of Lung Cancer, 2023-10, Vol.63 (5), p.488-488

2023

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

JTO clinical and research reports, 2022-09, Vol.3 (9), p.100385-100385, Article 100385

2022

Volltextzugriff (PDF)

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

Clinical & translational oncology, 2009-07, Vol.11 (7), p.446-454

2009

Volltextzugriff (PDF)

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS282-TPS282

2023

Volltextzugriff (PDF)

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical cancer research, 2019-05, Vol.25 (10), p.3193-3193

2019

Volltextzugriff (PDF)

Abstract 543: IL-11, a novel diagnostic biomarker for lung adenocarcinoma, is involved in lung cancer tumorigenesis

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.543-543

2018

Volltextzugriff (PDF)

Prospective and observational study of the patient informed consent for clinical trials with drugs

Medicina clínica, 2008-10, Vol.131 (11), p.422-425

Ordovás Baines, Juan Pablo

2008

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer, 2020-11, Vol.126 (22), p.4867-4877

2020

Volltextzugriff (PDF)

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The lancet oncology, 2012-03, Vol.13 (3), p.239-246

2012

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Volltextzugriff (PDF)

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

Cancer discovery, 2020-11, Vol.10 (11), p.1635-1644

2020

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(78)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(45)
Oncology
(42)
Humans
(33)
Female
(20)
Lung Cancer
(20)
Male
(19)
Middle Aged
(18)
Lung Neoplasms - Drug Therapy
(17)
Chemotherapy
(16)
Aged
(15)
Immunotherapy
(13)
Mutation
(13)
Cancer Therapies
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(11)
Lung Neoplasms - Genetics
(11)
Lung Neoplasms - Pathology
(11)
Adult
(10)
Non-Small Cell Lung Carcinoma
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Targeting EGFR in Lung Cancer: Current Standards and Developments

Targeting TIGIT: Strengthening the Immune Checkpoint Blockade

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Targeting EGFR in Lung Cancer: Current Standards and Developments

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Necitumumab: a new option for first-line treatment of squamous cell lung cancer

Impacto psicológico del COVID-19 en los pacientes de Oncología Médica, Hemato-Oncología y Oncología Radioterápica de un hospital público en España

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)

O25-3. Tarlatamab in small cell lung cancer : safety and efficacy analyzed by baseline brain metastasis

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Abstract 543: IL-11, a novel diagnostic biomarker for lung adenocarcinoma, is involved in lung cancer tumorigenesis

Prospective and observational study of the patient informed consent for clinical trials with drugs

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

Suchergebnisse filtern